UQ team to test therapeutic HPV vaccine
08 February, 2006 by Graeme O'NeillA research team at the University of Queensland, headed by Prof Ian Frazer, is said to have developed a new, therapeutic vaccine for genital warts, and is about to begin phase II trials in Australia and China.
Eqitx CEO says 'no cash flow issues'
07 February, 2006 by Helen SchullerMelbourne-based Eqitx (ASX:EQX) was asked by the ASX last week to explain its financial position following the announcement it had invested a further $500,000 to increase its equity in vaccine developer VacTX.
Over the counter, into the black
07 February, 2006 by Helen SchullerSingapore-based, ASX-listed Rockeby Biomed (ASX:RBY) has changed its focus and managing director Dr Sze Wee Tan has a positive outlook for this year. Helen Schuller reports.
Why Chance takes no chances on GM
07 February, 2006 by Graeme O'NeillWestern Australia's agriculture minister, Kim Chance, is taking what many are now seeing as an overly cautious stance on biotechnology. Graeme O'Neill reports.
Industry groups warn PBS changes dangerous for biotech
07 February, 2006 by Ruth BeranWidely-touted changes to Australia's Pharmaceutical Benefits Scheme (PBS) could cost the biotech industry more than AUD$300 million in investment annually, according to AusBiotech.
Local councils to join Victorian biotech industry
07 February, 2006 by Ruth BeranA new study identifying ways that local government can assist the biotech industry was launched by Victorian minister for innovation John Brumby yesterday.
In brief: BresaGen, Premier Bionics, Panbio, Eqitx
03 February, 2006 by Helen SchullerBresaGen has concluded an agreement with Indian firm BV BioCorp, to register and distribute BresaGen's G-CSF for leukaemia and an undisclosed product in India, Sri Lanka, Bangladesh, and Nepal.
Psiron CEO, CFO resign
02 February, 2006 by Ruth BeranJulie Nutting has stepped down as both CEO and director of Sydney-based Psiron (ASX:PSX), positions she has held since December 2003.
Science minister for WA
01 February, 2006 by Iain ScottWestern Australia's new premier, Alan Carpenter, has created a portfolio for science and innovation.
Biotech boosted in priority plan: CSIRO
01 February, 2006 by Ruth BeranCSIRO's biotechnology and life science programs will be strengthened, the organisation claimed yesterday in the launch of its research policies for 2006/07 and beyond.
In brief: Acrux, Proteome Systems, Panbio, Virax
31 January, 2006 by Staff WritersRoss Dobinson has been appointed as Acrux's (ASX:ACR) non-executive chairman, replacing Nuno D'Aquino who is stepping down due to private commitments. D'Aquino will continue as a non-executive director and will chair the board's Human Capital Committee.
WA minister cops flak from prestigious journal
31 January, 2006 by Graeme O'NeillInternational science journal Nature Biotechnology has taken the Western Australian agriculture minister Kim Chance to task for funding a supposedly independent study of the health effects of genetically modified food crops by an Adelaide research institute renowned for its anti-GM activism.
Sirtex posts positive net cash flow
31 January, 2006 by Ruth BeranSydney biomedical company Sirtex Medical (ASX:SRX) has posted a positive net cash flow for the second quarter of 2005/06 of AUD$1.46 million, an increase of 87 per cent on the previous quarter.
New $35m biotech VC fund launched in SA
30 January, 2006 by Graeme O'NeillSouth Australia's rapidly expanding biotechnology industry now has access to AUD$35 million in venture capital, with Bio Innovation SA securing a deal with one of Australia's most successful superannuation funds, MTAA Super.
In brief: Eqitx, Chemeq, NeuroSolutions
30 January, 2006 by Staff WritersMelbourne-based Eqitx (ASX:EQX) has invested a further AUD$500,000 in equity in VacTX, making its total investment in the vaccine developer $2.3 million to date.
